The Latest Breaking News from LLY

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on Friday recommending Eli Lilly and Co.’s (NYSE:LLY) donanemab for early symptomatic Alzheimer’s disease in adults with confirmed amyloid pathology who are apolipoprotein E ε4 (ApoE4) heterozygotes or non-carriers.

Eli Lilly is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit growth.

Options traders leaned bearish on LLY stock, but market demand data reveals conditional odds that may support near-term upside.

Eli Lilly has just acquired gene-editing company Verve Therapeutics.

Meta Platforms and Eli Lilly are two stocks that could perform stock splits down the road, and it's not just because of their high share prices.

Both companies have established a solid presence in the weight-loss drug market, but only one of them can lead.

Eli Lilly's growth is fueled by leading drug sales and a promising pipeline, suggesting a sustained upward trajectory for the pharmaceutical innovator.

While Eli Lilly has underperformed the Dow over the past year, analysts remain bullish about the stock’s prospects.

Knowing what Congressional leaders are buying can give investors insight into future legislation that could benefit these companies